Paper Details

  1. Home
  2. Paper Details

Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B.

Author: GluudC, KrogsgaardK, MathurinP, MellerupM T, PoynardT

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Pretreatment with glucocorticosteroids before treatment with alfa interferon in patients with hepatitis B 'e' antigen positive chronic hepatitis B may be more effective than treatment with alfa interferon alone with regard to loss of hepatitis B 'e' antigen and hepatitis B virus DNA.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Chronic hepatitis B has serious effects on morbidity and mortality. Alfa interferon has been shown to increase the rates of HBeAg-clearance as well as seroconversion to anti-HBe, but response rates are unsatisfactory. Glucocorticosteroid pretreatment may increase the response to alfa int...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD000345

データ提供：米国国立医学図書館（NLM）

Combating Hepatitis B: Glucocorticosteroids and Alfa Interferon

Chronic hepatitis B (CHB) remains a significant global health concern, posing serious threats to morbidity and mortality. While alfa interferon has demonstrated some effectiveness in treating CHB, response rates remain unsatisfactory. This study investigates the potential benefits of combining glucocorticosteroids with alfa interferon for treating HBeAg-positive CHB. The researchers conducted a meta-analysis of 13 randomized trials, finding that sequential combination therapy with glucocorticosteroids and alfa interferon resulted in significantly higher rates of HBeAg and HBV DNA loss compared to alfa interferon alone. This suggests that combining these therapies could enhance the efficacy of CHB treatment.

A New Approach to Combating Hepatitis B: A Combination Therapy

This study highlights the potential benefits of combining glucocorticosteroids with alfa interferon for treating HBeAg-positive CHB. The researchers' findings suggest that this combination therapy leads to significantly higher rates of HBeAg and HBV DNA loss, offering a potentially more effective approach to managing this challenging disease. This could lead to improved treatment outcomes for patients with CHB, offering them a brighter path towards recovery.

A Promising Avenue in the Fight Against Hepatitis B: Combining Therapies

This research underscores the potential of combination therapy with glucocorticosteroids and alfa interferon in managing CHB. The researchers' findings suggest that this approach could lead to improved treatment outcomes, offering hope for individuals battling this debilitating disease. This research highlights the importance of exploring novel treatment strategies and combining therapies to achieve better outcomes in the fight against CHB.

Dr.Camel's Conclusion

This study suggests that combining glucocorticosteroids with alfa interferon could enhance the efficacy of CHB treatment. The findings demonstrate significantly higher rates of HBeAg and HBV DNA loss with this combination therapy, offering a potentially more effective approach to managing this challenging disease.

Date :
  1. Date Completed 2002-08-09
  2. Date Revised 2018-12-21
Further Info :

Pubmed ID

12076393

DOI: Digital Object Identifier

10.1002/14651858.CD000345

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.